Today’s invited guest blogger is Denis Bouchard from Taiwan. Please check out his long-term historic viewpoint on Fibonacci waves and how he comes to view today’s market. Feel free to comment  on this blog.

=====================================

Elliott Wave Insights, Part IV The End of a Six Thousand Year Elliott Wave Cycle

It has been several years since Elliott Wave Insights, Part III was published. With the major markets near the cusp of a directional change, the present is a very appropriate time to take several steps back and consider the overall picture of the wave pattern. A bird’s eye view of Elliott Waves from the beginning of human history may give us insights as to what lies ahead.

Strictly speaking the earliest stock market records are to be found in

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Friday November 13, 2009

DrStockPick.com Stock Report!

CEPH, PWRM

**************************************************************

CEPH, Cephalon Inc.

CEPH engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas.

According to a Securities and Exchange Commission filing yesterday, CEPH will give Barr Pharmaceuticals Inc. (which now is part of Israel-based Teva Pharmaceutical Industries) a license to sell a generic version of the pain drug Fentora in 2018 as part of a patent lawsuit settlement.

More about CEPH at www.cephalon.com

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer

...

By Cees Bruggemans, Chief Economist FNB.

After a great fall (2008), success in arresting the fall and stabilizing the economy on a low level of capacity utilization (2009), growth prospects tend to be very promising as slack resources as well as new inputs will be available to be put to work. Demand needs to grow in order to put such available resources to work.

Potentially this will be so for years to come (2010-2020) as any new supply imbalances eventually ending the next growth expansion (balance of payments, inflation) could remain manageable for the time being.

This, in a nutshell, is the case for growth.

It then gets better, but it also gets worse. For the global environment looks even better than this simple base case, offering piggyback opportunities for small open economies like ourselves.

This very favourable global environment, however, may also prove to offer a too rich

...

Syneron Medical Ltd. (ELOS) announced the commercial launch of the elure topical skin whitening products in several Asian markets. The company will sell these products through its dermatologists, beauty salons and spas in Asia from the first quarter of 2010.   The elure skin whitening product is an enzymatic skin whitening treatment that targets and decomposes melanin to reveal a visibly lighter and exceptionally luminous skin tone. The product uses a naturally occurring bio-active substance, Melanozyme, which decomposes the melanin in a fast and safe manner with no side effects.

In the process, Melanozyme is combined with a bio-activator to diminish the dark colored pigment in the skin. The use of Melanozyme eliminates side effects such as skin redness and burning sensation which are seen in the case of other skin whitening products available in the market.

It has been estimated that skin whitening is one of the fastest growing segments

...

Metalink Ltd. reported a net loss of $4.0 million, or $0.16 per share, in the third quarter of 2009. These results were slightly worse than the $3.0 million, or $0.13 per share, the company lost in the same quarter last year. Revenues were $500,000 in the third quarter of 2009 compared to $800,000 in the same quarter last year.

Metalink Ltd. has had a difficult time during the recession due to a drop in orders from its customers. The company received a warning from its auditors in March 2009, expressing doubts about its ability to continue as a going concern.

Although Metalink Ltd. held cash and equivalents of $3.8 million as of September 30, 2009, the company has significant short-term debt on its balance sheet, totaling $4.3 million. During the quarter, the company successfully renegotiated a large portion of its short term debt, and extended the term.

Metalink

...

The report below comes courtesy of Nouriel Roubini’s team of analysts at RGE, taking a look at some recent monetary policy trends in advanced economies. This content is excerpted from a longer piece, “Global Monetary Policy Review,” which includes in-depth analysis of when the world’s emerging markets might shift interest rate strategy. However, the longer piece is available only on a subscription basis.

Last week was a busy one for the Federal Reserve (Fed), the European Central Bank (ECB) and the Bank of England (BoE). Policymaking is tricky when different asset classes are sending very different signals about the economy. However, those different signals are themselves a byproduct of policy. In the US, bond markets are discounting a sluggish U-shaped recovery or even a double-dip recession, while risky markets are signaling a strong V-shaped recovery ahead. Which is right? While RGE leans towards the

...

Teva Pharmaceutical Industries Ltd. (TEVA) reported earnings of 89 cents in the third quarter of 2009, up 16% from the year-ago period and a cent above the Zacks Consensus Estimate. Strong sales of Copaxone and in the respiratory business helped drive earnings in the reported quarter. Net sales increased 25% to $3.55 billion, with the Barr acquisition contributing to sales across different geographical segments. The strengthening U.S. dollar adversely impacted net sales by $160 million or 6%. Revenue performance across key business segments was mixed. While the Pharmaceuticals Sales segment posted growth of 27% with revenues coming in at $3.4 billion, the active pharmaceutical ingredients (API) segment reported an 8% decline in growth with sales coming in at $136 million. Pharmaceutical segment sales were driven by strong performances in the North American, European and International segments. The launch of generic versions of Ortho Tri-Cyclen Lo ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Thursday October 29, 2009, are:

**************************************************************

AKAM, Akamai Technologies Inc.

AKAM provides market-leading managed services for powering video, dynamic transactions, and enterprise applications online.

AKAM’s Revenue for the third quarter 2009 was $206.5 million, a 5 percent increase over third quarter 2008 revenue of $197.3 million, and a 1 percent increase from second quarter 2009 revenue of $204.6 million.

More about AKAM at www.akamai.com

**************************************************************

CPE, Callon Petroleum Co.

CPE is engaged in the acquisition, development, exploration and operation of oil and gas properties primarily in the Gulf Coast region. CPE’s properties and operations are geographically concentrated in Louisiana,

...

We are initiating coverage of Oxygen Biotherapeutics, Inc. (OXBO) with an ‘Outperform’ rating. Despite what has been a tumultuous past for the company and a abysmal fate for competitors attempting to develop similar products, the potential upside that Oxycyte offers is too significant to ignore.  Does Oxycyte do what management says it does? (Key Efficacy Question) In theory, Oxycyte has the potential to be a wonder drug -- a sort of WD-40 of medicine. Preclinical data suggests that Oxycyte has astounding potential for the treatment of traumatic brain injury (TBI), decompression sickness, carbon monoxide poisoning, sickle cell crisis, organ preservation and as a neuroprotectant in patients with myocardial infarction or stroke. The effects in TBI were clearly evident in the phase I program conducted by Oxygen Bio in 2006. Initial phase II data from STOP-TBI will become available in 2010. However, data from small ...

EcoloCap Solutions Inc. will be hosting representatives from four continents in Korea this November in the first ever public unveiling of the company’s M-Fuel product, an innovative suspension fuel for use in diesel engines. M-Fuel, developed and manufactured by MBT (Micro Bubble Technologies), a subsidiary of EcoloCap Solutions Inc., is an innovative suspension fuel that far exceeds efficiencies for all conventional fuels. This environmentally-friendly and economical product is designed to offer fully scalable and customizable fuel solutions that increase efficiency, lower operating costs, and reduce emissions.

M-Fuel is a suspension mixture of 60% heavy oil, and 40% separated hydrogen and oxygen, plus a stabilizing additive. Nano Processing Units (NPUs) produce the fuel and can be configured to be integrated with an engine, producing fuel on demand, or the fuel can be pre-manufactured for delivery.

The event in Korea, scheduled for November 18th, will have representatives from more than

...